Suzhou Ribo Life Science Co., Ltd.

May 28, 2026 -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA based therapeutic for the treatment of coronary artery disease (CAD). Lately, Ribo has been advancing multiple siRNA candidates in parallel across atrial fibrillation and venous thromboembolism, and has established a world-leading anticoagulation/antithrombotic pipeline. This new submission for CAD represents an important milestone in Ribo's ambitious program to advance innovative oligonucleotide-based therapies aimed at systematically addressing the root cause of thromboembolic diseases. Coronary artery disease (CAD) remains a leading cause of morbidity and mortality globally, driven by atherosclerotic plaque formation and associated thrombotic complications such as myocardial infarction and other ischemic events. Despite the widespread use of standard of care therapies, including antiplatelet and anticoagulant therapies, a substantial residual risk of thrombotic events remains in patients with stable CAD, even when treated with optimized treatment. Current therapies are further limited by an increased risk of bleeding, restricting their intensity and long-term use in many patients. Consequently, there is a significant unmet medical need for novel antithrombotic approaches that can provide effective and sustained protection against thrombosis while maintaining a favorable safety profile, particularly with respect to bleeding risk. "We are very pleased to advance our anti-thrombotic siRNA programs into the next stage of clinical development in Europe. This milestone reflects our commitment to unlocking the full potential of RNA-based therapies to provide anticoagulant options with improved benefit-risk profile for patients not being adequately treated today." says Dr. Anders Gabrielsen, Chief Medical Officer of Ribo. The content above comes from the network. if any infringement, please contact us to modify.

A new platform collaboration positions generative AI drug discovery infrastructure at the center of RNA interference therapeutics development, as Insilico Medicine and Ribo formalize an arrangement that extends AI-guided design and automated experimental execution into the oligonucleotide modality. Insilico Medicine (HKEX: 03696.HK), a Hong Kong-listed AI drug discovery company, and Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938.HK), a clinical-stage oligonucleotide therapeutics company, announced a strategic collaboration agreement on May 12, 2026, combining Insilico’s Pharma.AI platform and LifeStar 2 automated laboratory with Ribo’s oligonucleotide therapeutics development capabilities. The arrangement deepens a pre-existing experimental services relationship and is structured to cover the full R\&D workflow, from target identification through clinical translation. Platform contributions and collaboration structure The Insilico Medicine Ribo collaboration is structured as a technology empowerment arrangement rather than an asset-specific co-development deal. Insilico contributes two core platform elements: Pharma.AI, its end-to-end generative AI drug discovery platform covering target screening, molecular design, data modeling, and clinical efficacy and safety prediction; and LifeStar 2, an automated biology laboratory with high-throughput experimental capacity. Ribo, which was listed on the Hong Kong Stock Exchange in January 2026, contributes domain expertise in oligonucleotide therapeutics development along with its vertically integrated R\&D infrastructure. Ribo’s platform suite includes RiboGalSTAR, a proprietary liver-targeting delivery technology that has advanced seven products to clinical stages across cardiovascular, metabolic, renal, and liver disease indications, and RiboPepSTAR, an extrahepatic delivery platform with preclinical evidence in kidney, cardiac, metabolic, and adipose tissue applications. The collaboration is intended to apply Insilico’s AI and automation layer across multiple stages of Ribo’s development workflow, including siRNA target discovery, drug molecule design and optimization, and AI-assisted clinical translation. No financial specifics of any kind were disclosed. Ribo noted that it had previously used Insilico’s LifeStar 2 laboratory for high-throughput experimental services, making it the first partner on that platform. The new agreement formalizes and expands that relationship into a broader strategic framework. AI drug discovery and RNA interference AI is already applied in oligonucleotide therapeutics development for target screening, sequence design, and data-driven prediction of clinical outcomes. The Insilico-Ribo collaboration seeks to extend those applications by integrating Pharma.AI’s generative design capabilities with Ribo’s modality-specific delivery platforms and clinical dataset infrastructure. In RNA interference therapeutics, target validation and sequence optimization represent early-stage bottlenecks where AI-guided approaches can reduce cycle time. Ribo’s RiboGalSTAR platform has demonstrated hepatic delivery efficiency across its clinical-stage pipeline, while RiboPepSTAR addresses the more technically challenging extrahepatic delivery problem. Applying Pharma.AI’s modeling capabilities to these programs could, according to the companies, improve the efficiency and certainty of candidate progression decisions. Insilico as a serial platform dealmaker The Ribo agreement reflects Insilico’s established strategy of deploying Pharma.AI and its automated lab infrastructure across modality-specific partners. In November 2025, Insilico entered a research and licensing collaboration with Eli Lilly to discover novel oral drug candidates against Lilly-selected targets, with Insilico eligible for over USD 100 million in upfront and milestone payments; that arrangement subsequently expanded into a USD 2.75 billion global R\&D collaboration in March 2026. In January 2026, Insilico announced an USD 888 million multi-year collaboration with Servier targeting oncology indications. Insilico has reported cumulative collaboration value of USD 4.6 billion across newly signed and existing agreements as of early 2026, with Pharma.AI software licensing relationships covering 13 of the world’s top 20 multinational pharmaceutical companies. The Ribo deal extends that platform deployment into oligonucleotide therapeutics, a modality not previously represented at scale in Insilico’s disclosed partnership portfolio. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

May 6, 2026 -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with Boehringer Ingelheim to discover novel therapies for liver disease, including metabolic dysfunction associated steatohepatitis (MASH). MASH is a serious and progressive form of fatty liver disease that can lead to fibrosis, cirrhosis, liver failure and liver cancer, affecting over 200 million people globally. Despite its growing burden, there remains a need for effective medicines that can help prevent disease progression and support liver health. Through the collaboration, Ribo and Boehringer Ingelheim aim to expand the pipeline of potential future treatment options for patients with MASH. "This is an important step forward and highlights the strength and maturity of our siRNA discovery and liver targeted delivery capabilities. We are proud how together we drove this highly innovative and novel program forward, making this achievement possible. Boehringer Ingelheim will continue to advance this program with the goal of bringing new options to people living with MASH," said Li-Ming Gan, co-CEO & Global R&D President of Ribo. siRNA therapeutics are designed to silence disease causing genes by targeting their messenger RNAs (mRNAs). Ribo's liver targeting delivery technology is intended to enable selective uptake in hepatocytes, with the goal of addressing targets that may be difficult to reach using traditional small molecules or antibodies. The milestone reflects the productivity of the Ribo–Boehringer Ingelheim collaboration and the shared ambition to pursue solutions to address unmet needs in liver and cardiometabolic disease. It solidifies Ribo's position as a strategic partner for global pharma, highlighting its siRNA platform's commercial potential. Ribo is committed to pushing the collaboration forward with continued success throughout 2026 and beyond. The content above comes from the network. if any infringement, please contact us to modify.